- Home
- RJF vs ALNY Comparison
RJF vs ALNY Comparison
Compare RJF & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RJF
- ALNY
- Stock Information
- Founded
- RJF 1962
- ALNY 2002
- Country
- RJF United States
- ALNY United States
- Employees
- RJF N/A
- ALNY N/A
- Industry
- RJF Investment Bankers/Brokers/Service
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- RJF Finance
- ALNY Health Care
- Exchange
- RJF Nasdaq
- ALNY Nasdaq
- Market Cap
- RJF 32.7B
- ALNY 33.1B
- IPO Year
- RJF N/A
- ALNY 2004
- Fundamental
- Price
- RJF $157.28
- ALNY $243.25
- Analyst Decision
- RJF Hold
- ALNY Buy
- Analyst Count
- RJF 13
- ALNY 23
- Target Price
- RJF $143.25
- ALNY $298.59
- AVG Volume (30 Days)
- RJF 1.2M
- ALNY 633.0K
- Earning Date
- RJF 01-29-2025
- ALNY 02-13-2025
- Dividend Yield
- RJF 1.27%
- ALNY N/A
- EPS Growth
- RJF 21.71
- ALNY N/A
- EPS
- RJF 9.70
- ALNY N/A
- Revenue
- RJF $12,797,000,000.00
- ALNY $2,094,795,000.00
- Revenue This Year
- RJF $11.37
- ALNY $25.09
- Revenue Next Year
- RJF $6.52
- ALNY $16.75
- P/E Ratio
- RJF $16.21
- ALNY N/A
- Revenue Growth
- RJF 11.18
- ALNY 21.54
- 52 Week Low
- RJF $104.24
- ALNY $141.98
- 52 Week High
- RJF $171.38
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- RJF 48.07
- ALNY 42.07
- Support Level
- RJF $149.62
- ALNY $233.41
- Resistance Level
- RJF $162.80
- ALNY $247.21
- Average True Range (ATR)
- RJF 3.00
- ALNY 7.84
- MACD
- RJF -1.43
- ALNY 0.04
- Stochastic Oscillator
- RJF 44.35
- ALNY 39.82
About RJF Raymond James Financial Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company supports more than 8,000 employee and independent contractor financial advisors across the United States, Canada, and the United Kingdom with over $1.2 trillion of assets under administration as of September 2023. Approximately 90% of the company's revenue is from the US and 70% is from the company's wealth-management segment.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.